Gary Marshall
Pediatric Infectious Diseases · Louisville, KYNPI 1720062268
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Pfizer at 32.4% of the total.
Across 274 payments — averaging $1443.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$128K
- Sanofi Pasteur Inc.$89K
- Modernatx, Inc.$48K
- GSK$44K
- Merck$42K
- Seqirus USA Inc$41K
- plus $4K from 2 others
Across 97 payments — averaging $15,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Sanofi Pasteur Inc.$144K
- GSK$55K
- AstraZeneca$38K
- Merck$33K
What the payments were for
- Consulting fees$230,07758%
- Speaking & faculty fees$114,95529%
- Grants$8000%
- Travel & lodging$42,22311%
- Food & beverage$7,3482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 81 | $128,299 |
| Sanofi Pasteur Inc. | 61 | $88,571 |
| Modernatx, Inc. | 18 | $47,527 |
| GSK | 28 | $43,857 |
| Merck | 54 | $42,336 |
| Seqirus USA Inc | 19 | $41,222 |
| Sobi, Inc | 1 | $2,280 |
| AstraZeneca | 12 | $1,312 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PENBRAYA$21,487
- NO PRODUCT DISCUSSED$19,089
- TRUMENBA$17,585
- Moderna Covid-19 Vaccine$16,600
- FLUZONE QUADRIVALENT$14,946
- ABRYSVO$10,823
- PREVNAR - 13$10,360
- BEXSERO$9,889
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$8,700
- PREVNAR 20$6,105
- MENACYW CONJUGATE VACCINE$5,490
- COMIRNATY$4,576
- Fluad Quadrivalent$4,024
- Synagis$2,280
- VAXELIS$940
How this compares
Too few pediatric infectious diseases providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in Louisville
- Victoria StatlerLouisville$16K
- Michael SmithLouisville$5K
- Shanna BartonLouisville$3K
- Navjyot VidwanLouisville$370
- Daniel BlattLouisville$125
- Kristina BryantLouisville$45
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.